Guideline update. VTE disease: which agents, and when.
Holten
Keith B
KB
Clinton Memorial Hospital/University of Cincinnati, Family Medicine Residency, Wilmington, Ohio, USA.
Merok
Joshua
J
D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D000077425:Fondaparinux; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D011134:Polysaccharides / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D011134:Polysaccharides; D014812:Vitamin K; D006493:Heparin; D000077425:Fondaparinux